Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
about
Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialCIViC databaseMMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Antiangiogenic therapy for glioblastoma: current status and future prospects.Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).Current status and future directions of anti-angiogenic therapy for gliomasPredictive biomarkers investigated in glioblastoma.Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.Liquid biopsies in patients with diffuse glioma.Emerging circulating biomarkers in glioblastoma: promises and challenges.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?New Directions in Anti-Angiogenic Therapy for Glioblastoma.Angiogenesis inhibitors in tackling recurrent glioblastoma.A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade gliomaPhase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.Predicting glioblastoma response to bevacizumab through marker profiling?Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
P2860
Q26824777-CAF2D418-A849-4D16-B5AE-B020B7A20163Q27612411-540A2C32-59F9-4510-9689-52EDF8BEB2C4Q27853354-163F9201-52F5-424C-AB62-28F3492734C8Q30737224-73A7F318-B9BB-4F8E-B7A0-FA7C1998E108Q34523319-52F906F1-DDE3-4FF3-A0BE-4D146B5E551BQ35756369-1786CA15-0CC4-4EBC-885A-B6EBCC3EE201Q35793888-BC211C38-12DB-4F80-BA3A-27D5EB679FF3Q35895174-0E22BB34-5B84-433C-BE37-897E402679DBQ36289595-DB1F0EB6-62BE-418C-8D61-048FFABABE58Q36539474-16751A83-BF82-4A9E-BB4D-963D561BB250Q36618235-CE5ADE33-F296-4DD2-8076-42AA4FCD991AQ38237337-1F54D918-46AF-4A9F-8CCA-9FBCC57BCA61Q38255001-4BF3E921-BFEB-409E-A9BC-075D40850266Q38365590-392199D5-DACA-472E-86AE-383740C0A105Q38591062-4E296F5A-E11D-41BC-BDCF-13D1B45D0A21Q38635290-2ABCE689-80C5-4C9B-BD85-8EE7ABBA2F1BQ39022941-C966F825-F5B8-40F7-867E-D67FA595F1FFQ39259089-CAF7E5CD-F55F-4650-87EB-5B4C30F4AA9DQ39616746-B6721D21-FA65-4CA5-8011-4C49FB2E72CCQ40997333-09A83A50-7342-4C39-89F5-B82D00484AA2Q41232766-12DAD21B-5EBD-46DE-939C-18D349C2E3FFQ42364151-E5950514-FAC0-438D-AB90-B2DEF10A7C1FQ42642023-6AB3028C-AE85-44BF-BC56-997BD4FD978EQ43071990-66095A43-AF54-4560-A3FE-57A306127E83Q49635346-A01CFB16-B2E2-4404-9D2D-8F30DD20D27BQ50057597-4E344D4D-56B6-47A8-BA30-40AE7131A14D
P2860
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Association of matrix metallop ...... r recurrent high-grade glioma.
@ast
Association of matrix metallop ...... r recurrent high-grade glioma.
@en
Association of matrix metallop ...... r recurrent high-grade glioma.
@nl
type
label
Association of matrix metallop ...... r recurrent high-grade glioma.
@ast
Association of matrix metallop ...... r recurrent high-grade glioma.
@en
Association of matrix metallop ...... r recurrent high-grade glioma.
@nl
altLabel
Association of matrix metallop ...... or recurrent high-grade glioma
@en
prefLabel
Association of matrix metallop ...... r recurrent high-grade glioma.
@ast
Association of matrix metallop ...... r recurrent high-grade glioma.
@en
Association of matrix metallop ...... r recurrent high-grade glioma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Association of matrix metallop ...... r recurrent high-grade glioma.
@en
P2093
Anderson Loundou
Antoine Carpentier
Celine Boucard
Emeline Tabouret
Marc Sanson
Maryline Barrie
Mona Matta
Olivier Chinot
Philippe Metellus
P2860
P356
10.1093/NEUONC/NOT226
P577
2014-03-01T00:00:00Z